Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review

PharmacoEconomics

Volumn 32, Issue 11, 2014, Pages 1079-1091

  Zueger, Patrick M ^a   Schultz, Neil M ^b   Lee, Todd A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; ROSIGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

AMPUTATION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC PATIENT; DRUG COST; GROSS NATIONAL PRODUCT; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LIFE EXPECTANCY; MONOTHERAPY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; ULCER; VISUAL DISORDER; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; HEALTH CARE COST;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; GLUCAGON-LIKE PEPTIDE 1; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84911002716     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0192-4     Document Type: Review

References (32)

1. Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367(14):1332–40.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States, 2011. Atlanta (GA): US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–79.
5. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–81.
6. Victoza (liraglutide) solution pi. Princeton, NJ: Novo Nordisk, Inc.; 2012.
7. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–55.
8. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
9. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Pract. 2013;19(2):327–36.
10. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90.
11. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32(7):1224–30.
12. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med. 2009;26(3):268–78.
13. Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health J Int Soc Pharmacoecon Outcomes Res. 2013;16(2):231–50.
14. Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Pharmacotherapy. 2009;29(11):1280–8.
15. Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Cardiovasc Diabetol. 2009;8:12.
16. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.
17. Pelletier EM, Pawaskar M, Smith PJ, Best JH, Chapman RH. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. J Med Econ. 2012;15(6):1039–50.
18. Thayer S, Wei W, Buysman E, et al. The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy. Adv Ther. 2013;30(12):1128–40.
19. DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther. 2014;31(2):202–16.
20. Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013;19(3):237–46.
21. Lee WC, Samyshkin Y, Langer J, Palmer JL. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. J Med Econ. 2012;15(Suppl 2):28–37.
22. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin. 2011;27(5):897–906.
23. Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther. 2010;32(10):1756–67.
24. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Med J Br Diabetic Assoc. 2012;29(3):313–20.
25. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clin Ther. 2011;33(11):1698–712.
26. Mezquita Raya P, Perez A, Ramirez de Arellano A, Briones T, Hunt B, Valentine WJ. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 2013;4(2):417–430.
27. Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care. 2012;28(4):436–44.
28. Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab. 2011;13(1):81–8.
29. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747–59.
30. Edejer TT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CL. Making choices in Health. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization Geneva; 2003.
31. Cobden DS, Niessen LW, Rutten FF, Redekop WK. Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach. Patient Prefer Adherence. 2010;4:283–90.
32. Asche CV, Hippler SE, Eurich DT. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus. Pharmacoeconomics. 2014;32(1):15–27.